Phase Ic Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Subjects With Renal Anemia on Dialysis
Latest Information Update: 23 May 2025
At a glance
- Drugs HEC 53856 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
Most Recent Events
- 15 May 2025 Status changed from not yet recruiting to completed.
- 18 Jun 2021 New trial record